Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stacey Hubay"'
Autor:
Anish Tejura, Ricardo Fernandes, Stacey Hubay, Matthew Scott Ernst, Mario Valdes, Anupam Batra
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4795-4817 (2024)
Renal cell carcinoma accounts for a significant proportion of cancer diagnoses in Canadians. Over the past several years, the management of renal cell cancers has undergone rapid changes in all prognostic risk categories, resulting in improved oncolo
Externí odkaz:
https://doaj.org/article/2898d872150d442d9c052c5b05b0d711
Autor:
Jaclyn M. Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K. W. Chan
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Introduction While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC), studies have suggested clinical benefit with this targeted agent. The objective of this study was to assess the cost-effectivenes
Externí odkaz:
https://doaj.org/article/c1bbb30ac34c42b8a02c2b3fde4cc77c
Autor:
Stacey Hubay, James Keech, Kelvin K. W. Chan, Elena Mow, Jaclyn Beca, Andrew G. Robinson, Kaiwan Raza, Shaun Walsh
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Introduction While no direct comparative data exist for crizotinib in ROS1+ non-small cell lung cancer (NSCLC), studies have suggested clinical benefit with this targeted agent. The objective of this study was to assess the cost-effectiveness of criz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f301b51a4314cafc7e98d4b8857faa9
https://doi.org/10.1186/s12885-021-08746-z
https://doi.org/10.1186/s12885-021-08746-z
Publikováno v:
Cureus
Extragonadal germ cell tumors (EGCTs) are uncommon, and those involving the prostate are rare. We report on a primary seminoma of the prostate in a 56-year-old male presenting with scrotal pain, urinary frequency and urgency, and erectile dysfunction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b10cd4ccd51a546f6bf95800d186c80
https://doi.org/10.7759/cureus.14264
https://doi.org/10.7759/cureus.14264
Autor:
Tarek Elfiki, Kelvin K. W. Chan, Muhammad Salim, Stacey Hubay, Monish Ahluwalia, Christopher J. O'Callaghan, Matthew C. Cheung, Derek J. Jonker, Dawn Marie Ng, Frederic Lemay, Jonathan M. Loree, Nicole Mittmann, John Lenehan, Eric Chen, Nazik Hammad, Jose Gerard Monzon, Ambika Parmar, Dongsheng Tu, Anouk Tremblay, Harriet Feilotter
Publikováno v:
Journal of Clinical Oncology. 39:e15581-e15581
e15581 Background: The randomized phase II CCTG CO.26 clinical trial investigated the use of combined durvalumab and tremelimumab vs. best supportive care (BSC) for patients with mCRC and suggested an increase in overall survival (OS). The largest be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5f69e78c08e97b5702d17e82c294ab5
https://doi.org/10.1200/jco.2021.39.15_suppl.e15581
https://doi.org/10.1200/jco.2021.39.15_suppl.e15581
Autor:
Srikala S. Sridhar, Fred Saad, Stacey Hubay, Scott R. Berry, Helene Leonard, Daniel Yokom, John Stewart, Eric Winquist, Nimira S. Alimohamed, Jean-Baptiste Lattouf, Carla Girolametto
Introduction: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e92fe4ef0d9417a390f07c2748f85fde
https://europepmc.org/articles/PMC6114156/
https://europepmc.org/articles/PMC6114156/
Autor:
Jean-Baptiste Lattouf, Piotr Czaykowski, Fred Saad, Eric Winquist, Stacey Hubay, Karine Alloul, Nathalie Aucoin, Hussein Assi, Éric Lévesque, Scott M. Berry, John Stewart, Srikala S. Sridhar
Introduction: In the TROPIC study, cabazitaxel improved overall survival in abiraterone-naïve metastatic castration-resistant prostate cancer (mCRPC) patients post-docetaxel. To evaluate cabazitaxel in routine clinical practice, an international, si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43d71aee34e9655097a73da99815bed
https://europepmc.org/articles/PMC4839990/
https://europepmc.org/articles/PMC4839990/
Autor:
Tejura, Anish1,2 (AUTHOR) anish.tejura@lhsc.on.ca, Fernandes, Ricardo1,2 (AUTHOR) ricardo.fernandes@lhsc.on.ca, Hubay, Stacey3 (AUTHOR) stacey.hubay@grhosp.on.ca, Ernst, Matthew Scott3 (AUTHOR) matthew.ernst@grhosp.on.ca, Valdes, Mario3 (AUTHOR) mario.valdes@grhosp.on.ca, Batra, Anupam3 (AUTHOR) anupam.batra@grhosp.on.ca
Publikováno v:
Current Oncology. Aug2024, Vol. 31 Issue 8, p4795-4817. 23p.
Autor:
Stacey Hubay, Eric Winquist, Jean-Baptiste Lattouf, Nimira S. Alimohamed, Daniel Yokom, Scott R. Berry, Helene Leonard, Fred Saad, Carla Girolametto, Srikala S. Sridhar
Publikováno v:
Journal of Clinical Oncology. 33:281-281
281 Background: The TROPIC trial demonstrated that cabazitaxel improves overall survival (OS) in mCRPC patients progressing on or after docetaxel; a setting where both abiraterone and enzalutamide are also approved. We evaluated baseline factors that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::166a3b7414ca6a19b84ec3dbec90eb4d
https://doi.org/10.1200/jco.2015.33.7_suppl.281
https://doi.org/10.1200/jco.2015.33.7_suppl.281
Autor:
Stacey Hubay, Srikala S. Sridhar, Jean-Baptiste Lattouf, Hazem I. Assi, Piotr Czaykowski, Scott R. Berry, Karine Alloul, Eric Winquist, Fred Saad, Nathalie Aucoin, Éric Lévesque, John Stewart
Publikováno v:
Journal of Clinical Oncology. 32:5062-5062
5062^ Background: In the TROPIC study, Cbz was shown to improve overall survival in mCRPC pts post-docetaxel, however none of these pts had prior exposure to Abi. To better understand the impact of...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfc37078c78311667d080f46a773f760
https://doi.org/10.1200/jco.2014.32.15_suppl.5062
https://doi.org/10.1200/jco.2014.32.15_suppl.5062